{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:10:01Z","timestamp":1792757401924,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jad.2026.121257","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:52:44Z","timestamp":1769619164000},"page":"121257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies"],"prefix":"10.1016","volume":"401","author":[{"given":"Clara","family":"de Oliveira Lapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rubira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Jung Kurtz","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayra Catalina","family":"Coral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Antoni","family":"Ramos-Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Spanemberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.121257_bb0005","series-title":"Empirical Assessment of Within-Arm Correlation Imputation in Trials of Continuous Outcomes [Internet]","author":"Balk","year":"2012"},{"issue":"18","key":"10.1016\/j.jad.2026.121257_bb0010","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/cer-2022-0149","article-title":"Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study","volume":"11","author":"Brendle","year":"2022","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.jad.2026.121257_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.812938","article-title":"Suicidality and quality of life in treatment-resistant depression patients in Latin America: secondary interim analysis of the TRAL study","volume":"13","author":"Corral","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.121257_bb0020","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cpr.2010.06.001","article-title":"Self-reported versus clinician-rated symptoms of depression as outcome measures in psychotherapy research on depression: a meta-analysis","volume":"30","author":"Cuijpers","year":"2010","journal-title":"Clin. Psychol. Rev."},{"issue":"5","key":"10.1016\/j.jad.2026.121257_bb0025","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1570159X13666150630175044","article-title":"Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review","volume":"13","author":"D. Rosenblat","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"9","key":"10.1016\/j.jad.2026.121257_bb0030","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jad.2026.121257_bb0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpsychires.2024.04.008","article-title":"Efficacy of Esketamine among patients with treatment resistant depression in a \u2018real world\u2019 health-care setting in Israel","volume":"174","author":"Dvorak","year":"2024","journal-title":"J. Psychiatr. Res."},{"issue":"1\u20132","key":"10.1016\/j.jad.2026.121257_bb0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies","volume":"116","author":"Fekadu","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.jad.2026.121257_bb0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and meta-analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121257_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/02698811241267837","article-title":"Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment","volume":"39","author":"Guti\u00e9rrez-Rojas","year":"2025","journal-title":"J. Psychopharmacol. (Oxf.)"},{"issue":"3","key":"10.1016\/j.jad.2026.121257_bb0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clinthera.2024.12.006","article-title":"Health care resource use and medical costs among patients with major depressive disorder and acute suicidal ideation or behavior initiated on esketamine nasal spray or traditional treatments in the United States","volume":"47","author":"Harding","year":"2025","journal-title":"Clin. Ther."},{"issue":"S3","key":"10.1016\/j.jad.2026.121257_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-9338(02)00653-3","article-title":"Beyond the monoamine hypothesis: mechanisms, molecules and methods","volume":"17","author":"Hindmarch","year":"2002","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.121257_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.psycom.2024.100177","article-title":"A real-world study examining the impact of esketamine nasal spray in people living with major depressive disorder in Australia and New Zealand","volume":"4","author":"Hopwood","year":"2024","journal-title":"Psychiatry Res. Commun."},{"issue":"8","key":"10.1016\/j.jad.2026.121257_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3171","article-title":"Suicide-specific mortality among patients with treatment-resistant major depressive disorder, major depressive disorder with prior suicidal ideation or suicide attempts, or major depressive disorder alone","volume":"13","author":"Kern","year":"2023","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2026.121257_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.886918","article-title":"Glutamatergic system in depression and its role in neuromodulatory techniques optimization","volume":"13","author":"Khoodoruth","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2026.121257_bb0080","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/ph17091143","article-title":"A multi-center, open-label, single-arm study to investigate the early effectiveness of esketamine nasal spray in patients with treatment-resistant depression using a mobile self-monitoring application","volume":"17","author":"Kim","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.jad.2026.121257_bb0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0269881120978398","article-title":"Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity","volume":"35","author":"Lucchese","year":"2021","journal-title":"J. Psychopharmacol. (Oxf.)"},{"issue":"2","key":"10.1016\/j.jad.2026.121257_bb0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamapsychiatry.2022.3860","article-title":"Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study","volume":"80","author":"Lundberg","year":"2023","journal-title":"JAMA Psychiatr."},{"issue":"7","key":"10.1016\/j.jad.2026.121257_bb0095","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What is real-world data? A review of definitions based on literature and stakeholder interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jad.2026.121257_bb0100","doi-asserted-by":"crossref","DOI":"10.2174\/011570159X392347250929114024","article-title":"Gender differences in suicidal and self-harming responses to esketamine: a real-world retrospective study","author":"Martiadis","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2026.121257_bb0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121257_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2026.121257_bb0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","article-title":"Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review","volume":"32","author":"Molero","year":"2018","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.jad.2026.121257_bb0120","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s12325-025-03149-z","article-title":"A real-world study on the use, effectiveness, and safety of Esketamine nasal spray in patients with treatment-resistant depression: INTEGRATE study","volume":"42","author":"Molero","year":"2025","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.jad.2026.121257_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of Esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression\u2014TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2026.121257_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2025.120231","article-title":"Mentalization and emotional-cognitive rigidity as predictors of esketamine\u2019s effects on treatment-resistant depression: findings from a prospective observational study","volume":"392","author":"Olivola","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121257_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting outcome with intranasal esketamine treatment: a machine-learning, three-month study in treatment-resistant depression (ESK-LEARNING)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.jad.2026.121257_bb0140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.121257_bb0145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2174\/011570159X337670241029062524","article-title":"Esketamine treatment trajectory of patients with treatment-resistant depression in the mid and long-term run: data from REAL-ESK study group","volume":"23","author":"Rosso","year":"2025","journal-title":"Curr. Neuropharmacol."},{"issue":"9453","key":"10.1016\/j.jad.2026.121257_bb0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jad.2026.121257_bb0155","first-page":"19m12891","article-title":"J. Clin. Psychiatry","volume":"81","author":"Wajs","year":"2020"},{"key":"10.1016\/j.jad.2026.121257_bb0160","article-title":"Use of esketamine nasal spray in patients with treatment-resistant depression in routine practice: a real-world French study","volume":"2024(1):7262794","author":"Samalin","year":"2024","journal-title":"Depress. Anxiety"},{"issue":"23","key":"10.1016\/j.jad.2026.121257_bb0165","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence \u2014 what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.121257_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115165","article-title":"Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray","volume":"323","author":"Turkoz","year":"2023","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.jad.2026.121257_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.9758\/cpn.23.1097","article-title":"Treating treatment-resistant depression with esketamine nasal spray when all therapeutic options have been exhausted: clinical experience from a Spanish cohort of expanded use","volume":"22","author":"Vendrell-Serres","year":"2024","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.jad.2026.121257_bb0180","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.121257_bb0185","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.121257_bb0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1176\/appi.ajp.159.3.469","article-title":"Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?","volume":"159","author":"Zimmerman","year":"2002","journal-title":"Am. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:22:27Z","timestamp":1782188547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S0165032726001084"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121257","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121257"}}